URSZULA ORLINSKA, MPharm.Sci., PhD

***** ******* ****

Vista, CA 92084

Phone and Fax: 760-***-****

email: abm9jt@r.postjobfree.com

SUMMARY I am a research scientist graduated in pharmaceutical sciences

who integrated cell biology, immunology and pharmacology.

I have many years of experience in establishment of assays

and methods. Among them were in vitro assays, and cell-

based assays. I set up functional assays, for example, to

evaluate generation of inflammatory mediators such as

cytokines by inflammatory cells, and assays to identify

biomarkers, for example in bone cells. My methodological

experience include biochemistry of protein, namely protein

purification, separation and identification,

quantification of proteins with ELISA or receptor assays,

binding assays, separation of ligands, enzymology, labeling

of proteins and fluorescence microscopy, flow cytometry,

transfection assays, and other. I have a wide experience

with automation practiced in large clinical hospital

laboratories such as Clinical Chemistry at Duke University.

Identification of small molecules: At AstraZeneca

Pharmaceuticals I set up a high throughput screening method

to screen the entire chemical library to identify a small

molecule as C3convertase inhibitor. Also, at The DuPont

Merck Pharmaceuticals my scientific projects complemented

the HTS aimed to identify small molecule as IL-1beta

inhibitor.

Experience with therapeutics: I evaluated immunotherapeutic

steroids from the adrenal androgen pathway for their

beneficiary effect in reversing osteoporosis, improvement

of lost cognition in stroke or peripheral circulation.

Managed lead-optimization and SAR assays to support

medicinal chemistry.

Please refer to the body of my resume for more detailed

description of my research experience.

EXPERTISE -Uniquely competent in diverse research areas such as metabolic

regulation and inflammation in conjunction with immune

system function, circulation and CNS research.

-Initiated, developed and completed several diverse

research projects in their preclinical stage.

-Identified various targets, and evaluated mechanisms of

action and efficacies of tested drug candidates, in both in

vivo and in vitro models. Results were published or

patented.

-Experienced in enzymology.

-Established dynamic and efficient research collaborations

with several institutions.

-Set up from scratch and validated several laboratories

including the Morris Water Maze cognition testing

laboratory.

-Have team management experience in addition to

interdepartmental interactions.

SKILLS New research programs initiation and establishment, and to

implement animal models, and research methods and

procedures. Competent in comprehensive research, able to

manage multiple and diverse projects concurrently.

Motivated to learn new projects, and skilled to manage

them. Team oriented, scientifically flexible, and focused

on responsibilities.

OBJECTIVE Apply scientific knowledge and expertise to new drug

discovery and development.

SCIENTIFIC ON-THE-JOB ACCOMPLISHMENTS

Allergan, LLC, Irvine, CA 2007-2009

Scientist, Neurotoxin Pain Research

In vivo imaging, Microcirculation- Project Responsibility (hands on),

completed.

. Set up from scratch and validated the real time imaging method of

cutaneous blood perfusion to assess

blood perfusion in animals in relationship to both nociceptive and

non-nociceptive testing of molecules in native or transgenic mice.

. Responsible to identify and initiate new projects.

Hollis-Eden Pharmaceuticals, Inc., San Diego, CA 2001 - 2007

Senior Research Scientist, Metabolic Regulation and

Immuneregulation/Inflammation

Neuromusculoskeletal Research - Projects Leader and hands on,

completed.

CNS

. Initiated, and evaluated improvement of cognition by HE2200 in

stroke (collaboration with Prof. B. Pappas).

. Determined mechanism of action in brain tissue.

Results from this project has been published.

Osteoporosis

. Initiated, developed and took forward project of bone mass/quality

maintenance by adrenal androgens:

(1) in vivo (collaboration with Dr. Scott Miller), (2) in vitro,

(3) bone genes expression, (4) stem cells research. Mechanism of

anti-resorptive effect of HE3286 has been characterized, and

results published.

Contracted Projects: SAR of Adrenal Androgens/Mechanism of Action-

Projects Responsibility, completed.

. Immunosuppression in vivo: thymic involution and cold stress in

mice, and in vitro: apoptosis.

. Psoriasis in the mouse and eczema in g.pigs.

. Structure-activity relationship of immunoinflammatory mediators.

The Scripps Research Institute, La Jolla, CA 2000

National Training Program Award Fellow, Vascular Biology

Atherosclerosis (hands on)

. Evaluated reversal of hyperlipidemia, and aortic plaques in

ovariectomized, or castrated mice by adrenal androgens.

. Evaluated role of peripheral blood cells in an onset of

atherosclerosis and modification by steroids.

Results from these projects have been published.

AstraZeneca Pharmaceuticals, Wilmington, DE 1996 - 2000

Senior Research Bioscientist, Central Nervous System R&D

Neuroinflammation/Neurodegeneration and Cognition - Projects Leader,

completed.

. Determined efficacy of nominated compound in MS model.

. Developed complete research cascade for a project titled

"inhibition of complement system by small molecules", including HTS

assay.

. Organized from scratch and validated the Neuromnemonics Laboratory

involved in the testing of compounds for cognition improvement.

For 10 years this laboratory became central facility in CNS

research at AstraZeneca Pharmaceuticals in Wilmington, DE.

. Developed in vivo models with characteristics of

neurodegeneration/CNS inflammation for multiple CNS targets: stab

wound brain injury, brain microglial cells, kainic acid-induced

ChAT activity.

. Adapted methodology, and evaluated cholesterol metabolism as a

mechanism of action for compounds developed for stroke and memory

improvement.

. Initiated neurosteroids pharmacology: co-developed and led project

titled "brain cyp7b inhibitor" in relationship to memory

improvement.

Collaboration with Academia

Established dynamic and productive collaborations with Johns

Hopkins University (Dr. Alicja Markowska) and Carleton University

(Dr. Bruce Pappas) on testing tamoxifen in animal models relevant

to Alzheimer's dementia.

Pharmadigm Biosciences, Inc. (former PARADIGM), Salt Lake City, UT 1993 -

1995

Senior Scientist, Inflammation/Circulation, and Radiation Safety Officer

Vascular Pharmacodynamics,

and Pharmacokinetics of Adrenal Steroids - Projects Leader and hands

on, completed.

. Identified targets toward modification of expression/biological

activity of inflammatory mediators in hypoxia-reperfusion injury,

and skin edema.

. Discovered that in ferrets DHEA functions as a Ca2+-dependent K+

channel opener. Importantly, this observation was reproduced in

human pulmonary artery smooth muscle cell.

. Discovered that glutathione preservation in lung by DHEA restores

completely airways function in rats.

. Pharmacokinetic and safety studies.

. Clinical study phase I.

Results from various studies have been published, or patented.

The M.S. Hershey Medical Center, Hershey, PA 1992 - 1993

Postdoctoral Fellow, Department of Pathology

Pulmonary Fibrosis in Coal Miners/Inflammation (hands on),

completed.

. Characterized interrelationship between inflammatory mediators

involved in onset of pulmonary fibrosis in rats.

. Investigated role of TGF-beta in function of lung macrophage

isolated from silica exposed rats, or coal miners diagnosed with

pulmonary fibrosis.

Results have been published.

The DuPont Merck Pharmaceutical Co., Glenolden, PA 1989 - 1992

Postdoctoral Fellow, Inflammatory Diseases Research

Mechanism(s) of Interleukin-1 and TNF-alpha Production, and Export,

in Lipopolysaccharide-activated Human Monocytes - Projects Leader and

hands on, completed.

This project complemented company project entitled "IL-1

inhibitor".

. Characterized the plasma membrane ionic exchanges in relationship

to IL-1 and TNFalpha generation in human monocytes.

. Resolved the roles of glucose, and glucose transporter in IL-1

and TNFalpha export from human monocytes.

. Identified an IL-1 plasma specific glycoprotein (transporter?).

. Contributed to an establishment of projects in Inflammation.

Results have been published in several manuscripts. Data

describing the interrelationship between ionic fluxes and IL-1

secretion by human LPS-activated moncsytes has been reproduced, and

published by researchers from Pfizer.

SCIENTIFIC EXPERTISE

I. Animal modeling:

. Immune regulation

Glucocorticoids-dependent immunosuppression, eczema and

psoriasis.

. Metabolic diseases/Inflammation

atherosclerosis, osteoporosis.

. Pulmonary disorders/Inflammation

Monocrotaline and hypoxia-induced pulmonary hypertension, hyperoxia

or burn-induced lung injury,

dust-induced pulmonary fibrosis.

. Microcirculation

Hypoxia-reperfusion injury, real time imaging of cutaneous blood

flow

. Behavioral Neuroscience

Learning and memory measuring tests, specifically the Morris

water maze, dry land T maze and the water T-maze.

. Neurodegeneration/Neuroinflammation

MS, stroke, hypoxia and glucocorticoid-induced neuronal damage,

stab wound, chronic brain hypoperfusion-induced Alzheimer's

dementia, models of neurodegeneration.

II. In vitro/Ex vivo

Cell physiology/immunology:

. Human peripheral blood cell purification and culture

including monocytes, neutrophils, platelets and lymphocytes.

. Fractionation of splenocytes from mice spleens for activation

toward inflammatory mediators production.

. T cell role in brain acute inflammation.

. Ions exchange-dependent generation of inflammatory mediators

by macrophage.

. Interrelationship between glucose transporter function and IL-

1beta generation.

. IL-1beta transporter function in human macrophage plasma

membrane.

. Modification of K+ channels in pulmonary artery and vascular

smooth muscle cell by steroids.

. Modification of endothelial cell function in hypoxia-

reperfusion injury by adrenal steroids.

. Role of endothelial cell in on-set of pulmonary hypertension.

. Interaction(s) between endothelial cell and vascular smooth

muscle cell in an onset of vascular pathologies.

. Role of inflammatory mediators in onset of aging.

. Bone homeostasis:

osteoblast biology, and osteoclast biology:

-evaluation of process of maturation of precursors to mature

osteoclast,

-identification of NFkB as a target for adrenal steroids,

-NFkB, RANK, and RANKL interrelationship modification by adrenal

steroids.

. Isolated lung perfusion.

. Brain: -microglial cell, -tissue immunohistology, -cyp7b

activity,-ChAT activity, -glial cell (collaboration with

Prof. B. Pappas).

III. Developed/Utilized the following systems:

. Tissue Culture: microglia; pulmonary artery and dermal

microvascular endothelial cell; pulmonary artery smooth muscle

cell; epithelial cell and fibroblast cell lines; monocyte

(human) and macrophage (human, rat and monkey); basophil and

mast cell; fractionation of human monocytes, neutrophils,

lymphocytes and platelets; osteoblast cell line;

. Techniques: established real time imaging method to evaluate the

cutaneous blood perfusion; flow cytometry; immunocytochemistry

and fluorescence microscopy, HTS and automation experience,

protein analysis: developed HPLC methods; purification and

separation techniques; determination of cellular and membrane

enzyme activities and functions; receptor-ligand binding

analysis; spectrophotometric and fluorometric analyses; ELISA

and radioimmunoassay; HTRF methodology; transfection assay; RNA

isolation.

IV. Molecular Pharmacology:

4 Bone gene expression regulation by steroids.

GRANTS and AWARDS

. Financial award for outstanding Grade Point Average during

the second year of Graduate School, Poland.

. Co-author of a $1 million grant proposal to NIH on The Role of TGF-

1 and Polyamines in the Pathology of Pulmonary Hypertension, 1989,

funded.

. Co-author of a grant proposal to Generic Mineral Technology Center

For Respirable Dust Industry (University Park, PA) on The Multiple

Role of Transforming Growth Factor- 1 in Pneumoconiosis in Coal

Miners, 1992, funded.

. Author of a grant proposal to The Small Business Innovation

Research Program (NIH) on Increased platelet sensitivity in aging:

possible linkage to losses in adrenal androgen production, 1994,

submission of grant postponed.

. Recipient of 2000 Travel Stipend for Merit Awards for Young

Investigators from the American Heart Association.

. National Training Program Award Fellow, 2000 (Scripps).

. U.Orlinska and B.A.Pappas "Improvement of learning and memory by

adrenal androgens", Institute for the Study of Aging, April 2003,

not funded . Animal models: stroke and chronic glucocorticoid

exposure.

PATENTS

USA: GRANTED

U.S. Patent Number 5,753,640/May 19, 1998,

U.S. Patent Number 5,846,963/December 8, 1998

U.S. Patent Number 5,977,095/November 11, 1999

U.S. Patent Number 6,150,348/November 21, 2000

U.S. Patent Number 6,187,767/February 13, 2001

Pharmadigm, Inc. and Univ. of Utah Research Foundation

B.A. Araneo, U. Orlinska, and I.S. Farrukh "Methods for preventing

progressive tissue necrosis, reperfusion injury, bacterial

translocation and adult respiratory distress syndrome".

WORLDWIDE: GRANTED, Australia,

Patent Number 747137/August 22, 2002

Pharmadigm, Inc. and Univ. of Utah Research Foundation,

B.A. Araneo, R. Daynes, U. Orlinska, and I.S. Farrukh "Methods for

preventing progressive tissue necrosis, reperfusion injury, bacterial

translocation and adult respiratory distress syndrome".

WORLDWIDE: PENDING

PCT/US95/10990, Reference 2325-115 Australia, Canada, Finland, Norway

EPO, Patent Application, Number 95932345 . 2-2107 for designated

states: AT, BE, CH, LI, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,

PT, SE

B.A. Araneo, U. Orlinska, I.S. Farrukh, and R. A. Daynes

"Dehydroepiandrosterone derivatives for preventing progressive tissue

necrosis, reperfusion injury, bacterial translocation and adult

respiratory distress syndrome".

PUBLICATIONS

1. Orlinska U., Olson J.W. and Gillespie M.N. "Polyamine Content in

Pulmonary Arteries From Rats With Monocrotaline-Induced

Pulmonary Hypertension". Res. Commun. Chem. Pathol. Pharmacol.,

62, 2 (1988) 187-194.

2. Olson J. W., Allen-Gebb S., Orlinska U. and Gillespie M.N.

"Polyamine Synthesis in Rat Lungs Injured With Alpha-

Naphtylthiourea". Toxicology, 55, 3 (1989) 317-326.

3. Olson J.W., Orlinska U. and Gillespie M.N. "Polyamine Synthesis

Blockade Reverses Monocrotaline-Induced Pneumotoxicity".

Biochem. Pharmacol., 38, 17-198*-****-****.

4. Gillespie M.N., Rippetoe P.E., Haven C.A., Siao R.T., Orlinska

U., Maley B.E., and Olson J.W. "Polyamines and Epidermal Growth

Factor in Monocrotaline-Induced Pulmonary Hypertension". Am.

Rev. Respir. Dis., 140, 5-198*-****-****.

5. Orlinska U., Olson J.W., Allen-Gebb S., and Gillespie M.N.

"Acetylated Polyamines in Lungs From Rats With Monocrotaline-

Induced Pulmonary Hypertension". Fundam. Appl. Toxicol., 13, 2

(1989) 277-284.

6. Orlinska U. and Newton R.C. "Effects of Intracellular Ions on

Interleukin-1 Production by Lipopolysaccharide-Activated Human

Monocytes". Am. J. Physiol., 263, 5 (1992) C1073-C1080.

7. Orlinska U. and Newton R.C. "Role of Glucose in Interleukin-1

Production by Lipopolysaccharide-Activated Human Monocytes". J.

Cell. Physiol., 157 (1993) 201-208.

8. Orlinska U. and Newton R.C. "Modification of Tumor Necrosis

Factor-alpha (TNF-alpha) Production by the Na+dependent HCO3-

cotransport in Lipopolysaccharide-Activated Human Monocytes".

Immunopharmacology, 30 (1995)1, 41-50.

9. Orlinska U. and Kuhn D.C. "Regulation of TXB2 and PGE2

Production by TGF- 1in in vitro Silica Dust- Exposed Rat

Alveolar Macrophage". Mediators in Inflammation, 4, (1995) 6,

413-416.

10. Farrukh I. S., Peng W., Orlinska U. and Hoidal J.R. "Effect of

dehydroepiandrosterone on hypoxic pulmonary vasoconstriction: a

Ca2+activated K+ channel opener". Am. J. Physiol., 274, 18

(1998) L186-195.

11. Orlinska U. and Araneo B.A. " Dehydroepiandrosterone (DHEA)

reduces vascular permeability in the rat skin". Manuscript

completed.

12. Farrukh I.S. and Orlinska U. "Dehydroepiandrosterone prevents

lung failure in rats exposed to hyperoxia". Manuscript

completed.

13. Orlinska U. and C.L. Banka. "Castration accelerates

atherosclerosis in male LDL receptor-deficient mice".

Manuscript completed.

14. Orlinska U., M.M. Marsh, and C.L. Banka. "Relationship between

peripheral leukocytosis and atherosclerosis in LDL receptor-

deficient mice deprived of estrogen". Manuscript completed.

ABSTRACTS

1. Orlinska U., Henning B., Gillespie M.N. and Olson J.W.

"Transforming Growth Factor- (TGF- ) Induction of Endothelial

Cell Ornithine Decarboxylase (ODC)". J. Cell. Biochem.,

Supplement 13B (1989) A157.

2. Orlinska U., Olson J.W. and Gillespie M.N. "Detection of

Transforming Growth Factor- (TGF- ) in Lungs and Platelets From

Monocrotaline-Treated Rats". FASEB J., 3 (1989) A903.

3. Allen-Gebb S., Orlinska U., Olson J.W. and Gillespie M.N.

"Molecular Basis of Increased Ornithine Decarboxylase in Lungs

From Monocrotaline-Treated Rats". FASEB J., 3 (1989) A904.

4. Shiao R.-T., Orlinska U., Olson J.W. and Gillespie M.N. "The

Integrated Lung Polyamine Biosynthetic Response to Chronic

Hypoxia in Rats". FASEB J., 3 (1989) A904.

5. Shiao R.T., Orlinska U., Olson J. W., and Gillespie M.N.

"Mechanisms Promoting Lung Polyamine Accumulation in Chronically

Hypoxic Rats". Am. Rev. Resp. Dis., 141, 4, (1990) A91.

6. Olson J.W., Orlinska U., Allen-Gebb S., Henning B., and

Gillespie M.N. "Potential Signaling Pathway for Thrombin

Induction of Endothelial Cell (EC) Ornithine Decarboxylase

(ODC). J. Cell. Biochem., Supplement 14C (1990) A106.

7. Olson J.W., Orlinska U., and Gillespie M.N. "Evidence that

Transforming Growth Factor- 1 (TGF- 1) Stimulation of Pulmonary

Artery Smooth Muscle Cell (SMC) Collagen Synthesis is Polyamine-

Mediated." J. Cell. Biochem., Supplement 15C (1991) A129.

8. Orlinska U., and Newton R.C. "Role of Na+ in IL-1 Production

in LPS-Activated Monocytes". Bioscience Ediprint, Geneva (1991)

A453.

9. Orlinska U., and Newton R.C. "Cellular Energy and Glucose

Transporter in IL-1 Production in LPS-Activated Monocytes". J.

Cell. Biochem., Supplement 15E (1991) A-O314.

10. Orlinska U., and Newton R.C. "Modification of Tumor Necrosis

Factor-alpha Production Upon the Modulation of Na+/HCO3-

cotransport in Lipopolysaccharide- Activated Human

Monocytes". J. Cell. Biochem Supplement 16A (1992) A315.

11. Orlinska U., Kuhn D.C., Gaydos L.J., and Demers L.M. "Nitric

Oxide and Hydroxyl Radical in Thromboxane B2 and Transforming

Growth Factor- 1 Production in Rat Alveolar Macrophage Exposed

to Silica-Dust in Vitro". J. Cell. Biochem. Supplement 17E

(1993) A R509.

12. Orlinska U., Hennebold J., and Daynes R. A. "Increased platelet

sensitivity in aging: possible linkage to losses in adrenal

androgen production". FASEB J., 8 (1994) A1951.

13. Jurek M.A., Araneo B.A., and Orlinska U., "The modification of

CD18 on human neutrophils by dehydroepiandrosterone (DHEA)".

FASEB J., 9 (1995) A4626.

14. Orlinska U., Jurek M.A., Franklin R.A., Araneo B.A. and

Soderland C. "Human dermal microvascular endothelial cell

("stretched cell")-a model to study vascular events in

postischemia". FASEB J., 9 (1995) A2959.

15. Franklin R.A., Jurek M.A., Ricigliano J., Araneo B.A., and

Orlinska U. "Additive effect of glutathione and

dehydroepiandrosterone (DHEA) on platelet aggregation". FASEB

J., 9 (1995) A6036.

16. Orlinska U. and Araneo B.A. "Dehydroepiandrosterone (DHEA) and

dehydroepiandrosterone sulfate (DHEAS) inhibit capillary

permeability in rat skin". FASEB J, 10 (1996) A294.

17. Farrukh I.S., Peng W., Orlinska U., and Hoidal J.R.

"Dehydroepiandrosterone-mediated pulmonary vasodilation of

hypoxic ferret lungs: a novel mechanism". American Thoracic

Society, 1996.

18. Orlinska U. and C.L. Banka. "Castration accelerates

atherosclerosis in male LDL receptor-deficient mice".

Circulation. 10, 18, (2000) A1562.

19. Richard B.M., Meschter C., Orlinska U., Reading C. and Ahlem C.

"Effects of AET on microscopic lesions of ulcerative colitis in

a rat model of inflammatory bowel disease". J. Leukocyte

Biology, Supplement 2001, A294.

20. Orlinska U., Ahlem C., Reading C., Shelby J. and Miller S.

"Administration of beta-androstenetriol to burned mice modifies

bone loss, structure and dynamics." J. Leukocyte Biology,

Supplement 2001, A295.

21. Orlinska U., Marsh M.M., and Banka C.L. "Relationship between

peripheral leukocytosis and atherosclerosis in LDL receptor-

deficient mice deprived of estrogen". APS Conference titled

"Genome and Hormones: An Integrative Approach to Gender

Differences in Physiology" (2001) AP2-077.

22. Auci D.L., Orlinska U., Downing C., Meschter C., Morgan L.,

Richard B., Ahlem C. and Reading C. "HE2500, a stable synthetic

derivative of DHEA, significantly reduces or eliminates lesions

in murine model of psoriasis". 3rd International Congress on

Autoimmunity, Geneva, Switzerland (2002).

23. Banka C.L., Samad F. and Orlinska U. "Androstenedione and

atherosclerosis: a double-edged sword". Atheroscler. Thromb.

Vasc. Biol. 24 (2004) 51-136, P24, Oral Presentation.

24. Orlinska U., Miller S.C., Pappas B.A. and Reading C.L. "A

trophic anti-glucocorticoid action of HE2200". The Journal of

Musculoskeletal and Neuronal Interactions, 4, 2 (2004) OR09.

25. Orlinska U., Williams S., Villegas S., Li M., Ahlem C., White

S., Frincke J., Miller S., Flores-Riveros J. Bone sparing

effect of HE3286, a synthetic adrenal androstene compound with

improved metabolic stability, Bone, Supplement 2007, 116W.

26. Orlinska U., Bell D., Williams S. and Flores-Riveros J.

Osteoblastic properties of HE3286, a synthetic adrenal

androstene. Abstract completed.

ORAL PRESENTATIONS

Orlinska U., Miller S.C., Pappas B.A. and Reading C.L. "A trophic

anti-glucocorticoid action of HE2200".

4th International Workshop on Musculoskeletal and Neuronal

Interactions, O09, May, 2004.

MANAGERIAL/ADMINISTRATIVE EXPERIENCE

. Hollis-Eden Pharmaceuticals: responsible for setting-up

collaborations with academic and commercial laboratories.

. AstraZeneca Pharmaceuticals: managed scientifically and

rhetorically the entire project of organization of Neuromnemonics

Laboratory. Interacted on a team basis with scientists from

metabolism, toxicology, chemistry, and with staff from the Clinical

Development and Legal Departments. Supervised 5 reports.

. Paradigm Biosciences, Inc.: supervised a PhD.

. Pennsylvania State University: 2 reports, interdepartmental and

interinstitutional interactions with other groups of scientists

(physical chemists, physicists, engineers, and biologists), and

with physicians. Provided scientific administration for research

grant.

. DuPont Merck: 2 reports, extensive interdepartmental interactions

with other groups of scientists, and with management.

. Hospital, Poland, Head of Laboratory Medicine: managed 25 medical

technologists, responsibilities included budgeting and finance

management, clinical consultations, and overall clinical service in

non-stop operating hospital laboratory.

. Hospital, Poland, Head of Biochemistry: managed 15 medical

technologists, clinical consultant, and responsible for clinical

service in non-stop operating laboratory.

CLINICAL EXPERIENCE

Medical Technologist, Instructor in Medical Technology program Duke

University Hospital, NC; Pharmacy Technician, University of North

Carolina Hospital Pharmacy, Chapel Hill; Medical Technologist,

St.Mary's Hospital, Pierre, S.D; Head of Laboratory Medicine, Hospital

Poland; Pharmacist, Poland; Head of Biochemistry, Hospital Poland.

Evaluation and control of clinical data.

EDUCATION

Ph.D., Pharmaceutical Sciences, Cardiovascular and

Pulmonary Pharmacology,

University of Kentucky, School of Pharmacy, Lexington, KY

Dissertation: "Polyamines and TGF- 1 in Monocrotaline Pneumotoxicity

".

M.A., Clinical Analysis and Pathology, Poland

M.Sc., Pharmaceutical Sciences, Graduate School of

Pharmacy, Poland

Thesis: Toxicology, "The Activity of Adenosine Deaminase

in Brain of Rats Tracheally Injected with Manganese

Dioxide".

CERTIFICATION

Certified Medical Technologist (ASCP), USA.

Licensed Pharmacist, Poland

PERSONAL American and Polish citizenship

LANGUAGES English, Polish, German, Russian and Latin (reading).

COMMUNITY ACTIVITIES available upon request

Contact this candidate